RAS and BRAF mutated (MT) colorectal cancers (CRC) occur in >60% of CRC patients and are associated with poor outcome. Although the therapeutic armamentarium of CRC has increased over the last 2 decades, there are subgroups of RAS and BRAFMT CRC in urgent need for novel treatments.
The research is focused on the identification of novel targets and pathways that are particularly relevant to drug resistance in the context of RAS/BRAFMT at the bench and applying this at the bedside.
Dr Van Schaeybroeck is interested in PhD applications in the fields of;
Name: Ms Hajrah Khawaja
Years of Study: 2015-2018
Name: Ms. Lisa Rainey
Years of Study: 2014-2018
Country: Northern Ireland
Our dedicated hub for postgraduate students, providing state-of-the-art facilities for study, and high-quality training and development programmes within a diverse interdisciplinary community.The gateway to your postgraduate experience
Queen's University Belfast is committed to Equality, Diversity and Inclusion.
For more information please read our Equality and Diversity Policy.
Queen's University Belfast is registered with the Charity Commission for Northern Ireland NIC101788
VAT registration number: GB 254 7995 11